Not at Any Price: How ICER Robs Myeloma Patients of Life and Hope

The Institute for Clinical and Economic Review (ICER), a Boston-based not-for-profit organization describes itself as “a trustworthy, independent source to help assess how valuable a new drug really is.” ICER does this by recommending prices that, in its estimation,...

Are Biopharmaceutical Budget Caps Good Public Policy?

Medical innovation has generated significant gains in health over the past decades, but these advances have been accompanied by rapid growth in healthcare spending. Faced with a growing number of high-cost but high-impact innovations, some have argued to constrain...

Measuring the Value of Prescription Drugs

Escalating drug prices have alarmed physicians and the American public and led to calls for government price controls. Less visibly, they have also spawned a flurry of private-sector initiatives designed to help physicians, payers, and patients understand the value of...